Key points are not available for this paper at this time.
The promising labetuzumab-SN-38 conjugates developed showed selective therapeutic efficacy in human tumor models at nontoxic doses that were a fraction of the CPT-11 doses used.
Govindan et al. (Wed,) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: